|Ms. Adelene Q. Perkins||Chairman & CEO||850.97k||N/A||1960|
|Dr. Lawrence E. Bloch M.D., J.D.||Pres, Principal Accounting Officer & Treasurer||541.66k||N/A||1966|
|Mr. Seth A. Tasker J.D.||VP, Gen. Counsel & Sec.||354.18k||N/A||1979|
|Ms. Melissa Hackel||VP of Fin.||N/A||N/A||N/A|
|Dr. Jeffery L. Kutok M.D., Ph.D.||Chief Scientific Officer & Sr. VP||N/A||N/A||1967|
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib, as well as duvelisib program, including DUO study that is in randomized and monotherapy Phase III clinical study for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma; PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate; and AbbVie Inc. to develop and commercialize products containing duvelisib in oncology indications. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.
Infinity Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.